Johnson & Johnson presents new patient data related to nipocalimab, its investigational treatment for Sjögren’s disease. The company’s updates focus on how patients value changes in specific symptoms, alongside earlier Phase 2 findings.
According to outlets describing the announcement, a set of patient-experience results to be presented at the American College of Rheumatology (ACR) 2026 highlights that improving mouth dryness is reported as the most important symptom, followed by eye dryness, fatigue, and joint pain. The PR release also positions these patient insights alongside Phase 2 clinical data, including reported saliva production improvement, framing the information as a way to connect efficacy outcomes with patient-prioritized symptom relief.
Across the two sources provided, the emphasis differs slightly: one focuses broadly on the company presenting patient data for nipocalimab in Sjögren’s disease, while the other adds more detail about which symptoms patients rank highest and links those preferences to ongoing trial results.
